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Human TBX1 Missense Mutations Cause Gain of Function
Resulting in the Same Phenotype as 22q11.2 Deletions
Christiane Zweier, Heinrich Sticht, Inci Aydin-Yaylagu¨l, Christine E. Campbell, and Anita Rauch
Deletion 22q11.2 syndrome is the most frequent known microdeletion syndrome and is associated with a highly variable
phenotype, including DiGeorge and Shprintzen (velocardiofacial) syndromes. Although haploinsufﬁciency of the T-box
transcription factor gene TBX1 is thought to cause the phenotype, to date, only four different point mutations in TBX1
have been reported in association with six of the major features of 22q11.2 deletion syndrome. Although, for the two
truncating mutations, loss of function was previously shown, the pathomechanism of the missense mutations remains
unknown. We report a novel heterozygous missense mutation, H194Q, in a familial case of Shprintzen syndrome and
show that this and the two previously reported missense mutations result in gain of function, possibly through stabi-
lization of the protein dimer DNA complex. We therefore conclude that TBX1 gain-of-function mutations can result in
the same phenotypic spectrum as haploinsufﬁciency caused by loss-of-function mutations or deletions.
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The well-known recurrent ∼3-Mb microdeletion within
chromosomal band 22q11.2 is associated with a variety
of symptoms and syndromes,1–3 including DiGeorge syn-
drome (DGS [MIM 188400]) and Shprintzen (velocardio-
facial) syndrome (VCFS [MIM 192430]). The 22q11.2 de-
letion syndrome constitutes a major cause of congenital
heart disease (CHD), accounting for ∼5% of all CHD cases
among live births.4 It is also the second most common
causative diagnosis in mental retardation, accounting for
∼2.4% of patients with developmental delay.5 The major-
ity of patients harbor a deletion of either 3 or 1.5 Mb,
both of which include the TBX1 gene.6 Of the ∼30 com-
monly deleted genes, Tbx1 is the only gene that, after an
extensive functional analysis in the mouse, has been
found to be haploinsufﬁcient with a convincingly similar
phenotype to the human syndrome.7 TBX1 is a member
of a phylogenetically conserved family of genes that share
a common DNA-binding domain, the T-box. Like the re-
lated Xenopus T protein (Xbra), TBX1 was shown to bind
a palindromic T oligonucleotide as a dimer.8 TBX1 has
three isoforms (A, B, and C) that share exons 1–8 but differ
in the terminal exons 9A, 9B/10, and 9C.9,10 The 9C tran-
script is the only isoform highly conserved in mouse and
was shown to be the major transcript in humans.10 How-
ever, mutational analysis of a total of 162 patients without
deletion initially failed to identify pathogenically signif-
icant alterations in the human homolog TBX1.9–11 Only
in 2003, by the screening of 10 patients with DGS/VCFS
without deletion, Yagi et al. identiﬁedmissensemutations
in two patients with sporadic disease and one truncation
mutation segregating in a family with the characteristic
22q11.2 deletion phenotype.12 The truncation mutation
was shown to result in loss of function due to the deletion
of a C-terminal nuclear localization signal of TBX1.13 This
mutation and a novel C-terminal truncating mutation
identiﬁed in another family with the DGS/VCFS pheno-
type were also shown to result in lack of activation in
a transcriptional chloramphenicol acetyltransferase–
reporter assay.14 The two missense mutations reported by
Yagi et al., however, did not show any signiﬁcant effect
in a reporter assay by use of a GAL4-Tbx1 fusion protein.13
We now report a third missense mutation in TBX1 and
provide, for the ﬁrst time, experimental evidence that the
proteins encoded by these three missense mutations are
functionally distinguishable from the wild-type protein.
After informed consent for genetic analyses had been
obtained, we had tested a series of patients with DGS/
VCFS-like phenotype with a set of 10 FISH clones, to ex-
clude typical and atypical 22q11.2 deletions.6 Ten patients
without deletion and with a typical 22q11.2 deletion phe-
notype were then selected for mutational analysis of the
TBX1 gene by direct sequencing of all nine exons with
exon-intron boundaries, including the three isoforms of
exon 9 (GenBank). Direct sequencing of both strands by
use of BigDye Terminator Cycle Sequencing Kit v3.1 (Ap-
plied Biosystems) was analyzed with an ABI 3730 auto-
mated sequencer (Applied Biosystems). Primer sequences
and PCR conditions are available on request. In one of
these patients, we detected a heterozygous missense mu-
tation, c.582CrG, resulting in the substitution of an evo-
lutionary conserved histidine at position 194 by a gluta-
mine within the T-box domain (ﬁg. 1A–1C). This patient
of Turkish origin was referred to us at age 2 years because
of short stature and speech delay. He was born after 39
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Figure 1. Identiﬁcation of a mutation in the TBX1 gene in a family with the 22q11 deletion phenotype. A, Pedigree and electro-
pherograms of the mutated genomic sequence of exon 5 of the TBX1 gene from the affected family members and the unaffected mother.
The position of the mutated nucleotide is indicated by a black arrow; the identiﬁed mutation c.582CrG leads to the amino acid
substitution H194Q. B, Alignment of a part of the T-box domain of TBX1 with homologues from various species (UCSC Genome
Bioinformatics) and other members of the T-box family. The conserved amino acids are shown with a gray background, and similar
amino acids with a light gray background. Residue 194 is indicated with a black box. C, Scheme of TBX1C indicating the T-box (pink),
the novel H194Q mutation (red arrowhead), and the mutations published by Yagi et al.12 and Paylor et al.14
wk of gestation, with a birth weight of 2,660 g (1.9 SD)
and a heel-to-crown length of 46 cm (2.62 SD). At the
age of 3 years and 10 mo, he had short stature (height
92.4 cm,3.01 SD; weight 12.1 kg; BMI 14.17) and a head
circumference just below the 3rd percentile (47.5 cm).
Apart from an operated club foot, operated undescended
testicles, and an innocent cardiac murmur, he had no or-
ganic problems or anomalies. Although he reached motor
milestones within normal limits (sitting at age 6–7 mo;
walking at age 13–14 mo), his speech development was
delayed, with only ﬁve single words at age 2 years. He
therefore received logopedic therapy, and, at age 4 years,
he spoke in full sentences. His overall functioning was
estimated at the level of low-normal to borderline, but
formal testing was not possible so far. His facial features,
with small, upslanting palpebral ﬁssures, tubulous nose,
short mouth, micrognathia, low-set ears, and ﬂat malar
regions with broad cheeks, represented the typical facial
gestalt of DGS/VCFS; therefore, he had been considered
for TBX1 mutational analysis after exclusion of a 22q11.2
deletion. The patient’s father, who had the same facial
features and short stature (160 cm) but normal psycho-
motor development, was found to have the same hetero-
zygous H194Q mutation (ﬁg. 1A). This mutation was not
found in 384 control chromosomes from healthy Euro-
pean individuals. Since the H194Q mutation is located
within the T-box domain, it was considered to have a high
probability of affecting the function of the protein. To test
this hypothesis, we established a novel transcriptional re-
porter assay. In a cytomegalovirus (CMV) expression vec-
tor containing the complete cDNA of human TBX1 iso-
form C, we introduced the three mutations published by
Yagi et al.12 and our novel mutation, by use of site-directed
mutagenesis done according to the protocol provided by
the Quik Change Site Directed Mutagenesis Kit (Strata-
gene), with minor modiﬁcations.
While initial attempts to establish the assay in HEK293
cells demonstrated a very weak and inconsistent transcrip-
tional activity of TBX1C, transcriptional activity was
much higher in JEG3 cells, which are derived fromhuman
choriocarcinoma. Because JEG3 cells, in contrast to
HEK293 cells, constituently express TBX1, this difference
suggests that the presence of cofactors may be important
for proper TBX1 function. JEG3 cells (American type cul-
ture collection cell line HTB-36) cultivated in RPMI me-
dium with 10% fetal calf serum were cotransfected with
a CMV expression vector containing a complete wild-type
ormutantTBX1C cDNA and a luciferase reporter construct
with a herpes simplex thymidine kinase promoter either
with two palindromic T-box binding sites inserted up-
stream of the tk promoter (2xTtkGL2) or without (tkGL2),
as well as a renilla luciferase vector to normalize for trans-
fection efﬁciency. The luciferase reporter construct is sim-
ilar to that reported by Sinha et al.,8 except that 2xTtkGL2
has two palindromic T-sites, whereas 4xT2tkGL2 had four
T-half sites oriented head to tail. None of the TBX1 con-
structs had any effect on transcription of the tkGL2 re-
porter construct, which has no T-box binding sites (ﬁg.
2A and 2B). In comparison with the empty CMV vector,
the TBX1C wild type showed a 14–46-fold activation of
2xTtkGL2 in three different experiments with three in-
dependent transfections each (ﬁg. 2). As expected, the
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Figure 2. Transcriptional activation of a luciferase reporter constructs by wild-type (WT) and mutant TBX1C. A–D, JEG-3 cells were
transiently transfected with reporter constructs containing a promoter without the T-Box binding sites (tkGL2 [white bars]) or with T-
Box binding sites (2xTtkGL2, bars with different shades of gray). Cotransfection was performed with either a CMV control vector, the
TBX1C wild-type construct, or the mutant constructs. Results are normalized for transfection efﬁciency to a cotransfected renilla luciferase
vector and expressed as average values  SEM of three independent transfections. The results were conﬁrmed by repeating the triple
transfections and measurements for two to three times respectively. A and B, Representative examples of results of single experiments
with three independent transfections for each combination. In comparison to the CMV vector TBX1C shows a 30–40-fold increased
activation on a reporter containing T-Box binding elements (2xTtkGL2 [gray bars]), whereas there is virtually no activation of the
reporter construct without T-Box binding sites (tkGL2 [white bars]). The truncating mutation 1223delC shows a clear lack of activation,
whereas the missense mutations indicate an increase in activation of the luciferase reporter construct. Due to the small number of
measurements, none of these results from a single experiment reaches statistical signiﬁcance with the Mann-Whitney-Wilcoxon test.
Similar results were obtained with two further experiments with three independent transfections each (data not shown). C, To compare
results from independent experiments, the activity of mutant TBX1C was normalized to that of wild-type TBX1C, and P values were
obtained using the Mann-Whitney-Wilcoxon test for unpaired samples of totally nine independent transfections in three independent
experiments (six transfections in two experiments for 1223delC). D, To simulate heterozygosity of the mutations, cells were simultaneously
transfected with equal amounts of wild-type and mutant TBX1C construct DNA. No obvious difference was observed in comparison with
cells transfected with mutant TBX1C only.
truncating mutation reported by Yagi et al.12 (1223delC)
(ﬁg. 2A–2C) showed virtually no activation. As a novel
ﬁnding, the two missense mutations F148Y and G310S,
which had behaved similarly to wild type in the assay
done by Stoller et al.,13 exhibited a slight but reproducible
and statistically signiﬁcant increase in activation relative
to wild-type TBX1C in our assay (ﬁg. 2A and 2C). The
novel mutation H194Q showed an even larger increase in
activation (ﬁg. 2B and 2C). To better simulate the hetero-
zygous effect of the mutations, cells were also transfected
simultaneously with equal amounts of TBX1C wild-type
and mutant vectors. No obvious difference was observed
in comparison with cells transfected with mutants only
(ﬁg. 2D).
To exclude differences in TBX1 expression as the cause
of the activity enhancement, we established a real-time
PCR assay to analyze mRNA levels in the transfected cells.
Cells were cotransfected in duplicate with the TBX1 wild-
type or mutant vector and a renilla luciferase vector and
were harvested after 48 h. Quantitative multiplex PCRwas
performed with an exogenous TBX1-speciﬁc TaqMan
probe and a control probe detecting renilla luciferase, to
normalize for transfection efﬁciency. Data from quadru-
plicate measurements were analyzed using the DDCt
method as described elsewhere.15 Results showed no in-
crease in expression levels of the mutants compared with
that of the wild type (ﬁg. 3). These ﬁndings support a gain
of function rather than a dosage effect as the mechanism
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Figure 3. Expression of wild-type (WT) and mutant TBX1C in JEG3
cells. JEG3 cells were transiently transfected with CMV, wild-type
and mutant TBX1C and TBX1C expression measured with a Taqman
assay. No increased expression was observed for the mutants in
comparison to the wild type. Results are normalized for transfec-
tion efﬁciency against the cotransfected renilla vector and ex-
pressed as average value  SEM of quadruplicate measurements
of two independent transfections, respectively. By use of the Mann-
Whitney-Wilcoxon test for unpaired samples, P values for com-
parison with the wild-type levels are 1 each for F148Y and H194Q,
0.24 for G310S, and 0.44 for 1223delC.
responsible for the differential behavior of the wild type
and the TBX1 missense mutations in our assay. Never-
theless, the slightly lower mRNA level of the G310S con-
struct could at least partially account for its less pro-
nounced increase in transcriptional activity.
The T-box domain, which is highly conserved in all T-
box proteins,16 is responsible for DNA binding and is likely
important for dimerization of TBX1, whose three-dimen-
sional structure has not been determined so far. The three-
dimensional structure has been solved for the DNA-bind-
ing (T-box) domain of the TBX1 homologues TBX317 and
the Brachyury transcription factor, Xbra.18 Within the T-
box domain, TBX3 and Xbra share sequence identities of
59% and 48% with TBX1, respectively, which is sufﬁcient
to obtain a reliable model of the TBX1 tertiary structure.
Although TBX3 and Xbra share a highly similar three-
dimensional structure for the monomeric proteins, the
dimer interface—and thus the quaternary structure—dif-
fers signiﬁcantly.17 A detailed comparison of those residues
forming the dimer interface suggests that TBX1 is more
similar to Xbra than to TBX3. In particular, TBX1 contains
a 3-residue insertion (P248–K250) within the b-sheet that
forms the dimer interface in TBX3, leading to steric clashes
during TBX1 model building on the TBX3 template (data
not shown). This higher similarity of the interface be-
tween TBX1 and Xbra is also consistent with biochemical
data showing that Xbra and TBX1 bind 40 times more
strongly to a palindromic DNA binding site than to a sin-
gle site, whereas TBX2 (which shares 95% sequence iden-
tity with TBX3 in the T-box domain) binds only 4 times
stronger.17 This has led to the suggestion that T-box do-
main proteins fall into different groups that differ in their
dimerization properties and their ability to interact with
single sites of the palindromic binding sequence.8 Ac-
cordingly, TBX1 and Xbra were proposed to belong to
the same class, whereas TBX2 and TBX3 belong to a dif-
ferent class.17 Consistent with this observation, we found
that, in contrast to TBX2, TBX1 was not active on the
4xT2tkGL2 reporter construct established by Sinha et al.,8
in which four T-half sites are oriented head to tail (un-
published data). In this construct, the orientation of the
binding sites would perturb or prohibit interaction of the
putative dimer interfaces of T-box proteins bound to ad-
jacent binding sites.
On the basis of these considerations, the structure of
the TBX1 DNA binding domain was modeled on the basis
of the Xbra DNA crystal structure (Protein Data Bank
[PDB] code 1xbr),18 resulting in a dimeric protein with a
good overall geometry and no steric clashes. The model
of TBX1 was generated using SWISS-MODEL and Swiss-
PdbViewer19 for sequence alignment and for building the
three-dimensional structure. The quality of the model was
assessed using PROCHECK20 and WHAT_CHECK,21 and
this assessment did not reveal any steric clashes or unfa-
vorable geometries. Mutations were inserted using the Sy-
byl 6.9 program package (Tripos) and were subsequently
reﬁned by 100 steps of energy minimization. Hydrogen
bonds were identiﬁed using Insight II (Accelrys) with the
standard cutoff criteria, and protein-protein as well as pro-
tein-DNA contacts were analyzed using LIGPLOT.22
The dimer interface in TBX1 is formed by residues
D151–D155 and P200–K202, which are conserved overall
between TBX1 and Xbra. Interestingly, the two noncon-
served residues (D155 and K202) form an additional salt
bridge across the dimer interface of TBX1 (ﬁg. 4A), thus
supporting the correctness of the modeled quaternary
structure. In the ﬁrst step, the local effect of themutations
was examined by modeling the mutant proteins and by
analyzing the changes of the interactions at the site of the
mutation. F148 is a nonconserved residue within the fam-
ily of T-box transcription factors, and a serine is present
at the equivalent sequence position in TBX3 and Xbra.
Apart from hydrophobic packing, F148 does not form any
speciﬁc side-chain interactions (ﬁg. 4B). In contrast, the
hydroxyl group present in the side chain of the Y148 mu-
tant allows formation of a hydrogen bond to the backbone
carbonyl oxygen of M207 (ﬁg. 4C).
The second site of mutation located at position 194 con-
tains a histidine in TBX1, whereas other T-box transcrip-
tion factors generally possess a tyrosine at the respective
sequence position. The ring of H194 points toward the
loop containing G227 (ﬁg. 1D), but even if a protonation
of the histidine ring at Nd is assumed, the distance to the
backbone of G227 would be too large for the formation
of a hydrogen bond. This situation is predicted to be dif-
ferent in the H194Q mutant, since, because of the more
extended structure of the side chain, a hydrogen bond is
predicted to be formed between the side chain amide
Figure 4. A, Three-dimensional model of human Tbx1 in complex with DNA (orange). The subunits of the dimeric protein are shown
in backbone presentation (blue and cyan) and the a-helices and b-sheets are depicted schematically. The three loops predicted to form
the dimer interface are shown (magenta), and residues D155 and K202 that form salt bridges (black dotted lines) across the dimer
interface are shown in stick presentation. A prime distinguishes residues belonging to different subunits. Residues F148 and H194, for
which mutations were observed, are shown in stick presentation, and sequence positions that were predicted to form novel interactions
with these residues in the mutant proteins are shown as balls. The spatial vicinity (black boxes) of these residues is shown as an
enlargement for the wild-type and mutant proteins in panels B–E. B–E, Detailed analysis of the structural effects of F148Y and H194Q
mutants. Models of the wild-type and mutant proteins are shown in the left and right panels, respectively. Structurally important
residues are shown in stick presentation and are colored according to the atom types. Green dotted lines indicate important hydrogen
bonds, which are apparently affected by the mutations, and the site of the hydrogen bond is marked (green arrow). B and C, Effect of
the F148Y mutation. The presence of a tyrosine at position 148 allows the formation of a novel side-chain hydrogen bond to the
carbonyl oxygen of M207 (E), which cannot be formed by the phenylalanine in the wild type (D). D and E, Effect of the H194Q mutation.
The presence of a glutamine at position 194 allows the formation of a novel side-chain hydrogen bond to the carbonyl oxygen of G227
(E), which cannot be formed by the histidine in the wild type (D).
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Table 1. Overview of Phenotype in 22q11.2 Copy-Number Aberrations and TBX1 Mutations
Trait
TBX1 Stop
Mutation12,14
( )np 7
F148Y12
( )np 1
G310S12
( )np 1
H194Q
( )np 2
Deletion2
( )np 558
(%)
Duplication27
( )anp 35
(%)Patient Father
Congenital heart defect 3     57 19
Hypocalcemia 1     60 …
Cleft palate      9 33
Velopharyngeal insufﬁciency 3     32 59
Short stature      36 50
Mental retardation and/or
developmental delay    ()  38 91
Psychiatric disorders 2     3029 …
VCFS facial gestaltb 7     10012 …
NOTE.— p presence of trait;  p absence of trait.
a Patients with 22q11.2 duplication are characterized by a distinct facial dysmorphism with appearance of widely spaced eyes and superior
placement of eyebrows—that is, increased distance from eyebrow to upper eyelid crease; downslanting palpebral ﬁssures with or without ptosis;
mild micrognathia and/or retrognathia; and a long, narrow face.26
b Hallmarks of the VCFS facial gestalt are short and narrow palpebral ﬁssures; tubulous nose with wide and prominent root and bridge of the nose
and narrow alar base; small mouth, particularly in younger children; ﬂattened malar eminences; retrognathia; and low-set ears with deﬁcient upper
helices.30,31
group of Q194 and the backbone carbonyl oxygen ofG227
(ﬁg. 4E). Thus, both mutations are expected to increase
the protein stability by additional hydrogen bonds.
To assess the global effect of this stabilization on protein
function, the localization of themutations in the structure
was examined in more detail. Both mutations are directly
linked via loops to key residues of the predicted dimer
interface. F148 belongs to the same peptide stretch as
D155, and H194 to the same stretch as K202 (ﬁg. 4A). As
described above, D155 and K202 form salt bridges across
the predicted dimer interface and are thus expected to be
crucial for dimer formation and stabilization in TBX1. The
additional interactions found in the F148Y and H194Q
mutants are expected to stabilize the respective loops, thus
facilitating dimer formation. In addition, the mutations
might also increase the rigidity of the entire structure by
stabilizing the relative orientation of the predicted dimer
interface and the DNA-binding region of TBX1. For ex-
ample, G227, which is stabilized by an additional hydro-
gen bond in the H194Q mutant, is located proximal to
the residues N220 and S233, which are involved in DNA
binding. Thus, there might also exist an increased coop-
erativity between dimer formation and DNA binding in
the mutants. This would explain why Stoller et al.13 did
not detect any effect of the F148Y missense mutation by
use of GAL4 DNA-binding domain fusions that did not
involve T-box–DNA interactions.
In summary, molecular modeling suggests that—con-
sistent with their similar effects seen in our transcriptional
activity assay—the F148Y andH194Qmutationsmayhave
similar effects on the TBX1 structure, probably resulting
in an increased dimer stability and/or DNA-binding afﬁn-
ity. The G310S mutation reported by Yagi et al.12 also
showed an increased transcriptional activation. Residue
310 lies outside of but adjacent to the T-box and, therefore,
may also affect DNA binding and/or protein stabilization.
Alternatively, this mutation may alter protein function
through another mechanism.
The observation of an increased transcriptional activa-
tion induced by theTBX1missensemutationswas initially
surprising, because usually the DGS/VCFS phenotype re-
sults from haploinsufﬁciency due to a deletion in the
22q11.2 region or, as shown recently, to truncating mu-
tations within the TBX1C gene.12–14 Nevertheless, our ob-
servations are in accordance with ﬁndings in mice, in
which both over- and underexpression of Tbx1 resulted
in a phenotype similar to that of DGS/VCFS in humans.23,24
However, the human phenotype associated with dupli-
cation 22q11.2, although overlapping with the clinical
spectrum of the corresponding deletion, is distinct, with
a different facial gestalt (table 1).25–31 Because our novel
and the previously published12 TBX1 missense mutations
with increased transcriptional activity are associated with
the typical facial gestalt of 22q11.2 deletion, the effect of
these speciﬁc gain-of-function mutations that probably
enhance protein stabilization seems to be a better phe-
nocopy of 22q11.2 deletion than that of increased22q11.2
dosage. Apart from the characteristic facial gestalt, pa-
tients with TBX1 point mutations, like patients with
22q11.2 deletion, show a large phenotypical variability
even within the same family, including congenital heart
defects, abnormal thymus and parathyreoid, velophar-
yngeal dysfunction, and psychiatric disorders.12,14 Our ob-
servation adds short stature and, possibly, developmental
delay to the phenotypic spectrum of TBX1 mutations. In
22q11.2 deletion, this variability is thought to be caused
by modifying genes inside or outside the deletion.32–36 Al-
though both features are part of the 22q11.2 deletion spec-
trum,2 our index patient is the only patient with TBX1
point mutation yet reported to show developmental
delay.12,14 Therefore, an additional factor causing the boy’s
developmental problems cannot be excluded. Analyses
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concerning chromosomal abnormalities, subtelomeric re-
arrangements, fragile-X syndrome, and skewed X inacti-
vation in the mother revealed normal results. Neverthe-
less, further studies are necessary to conﬁrm an association
between developmental delay and aTBX1 pointmutation.
In summary, we report the third missense mutation and
the ﬁfth overall mutation in TBX1 expanding the asso-
ciated phenotype to include short stature and, possibly,
developmental delay. We provide the ﬁrst evidence that
TBX1 missense mutations may alter the transcriptional
activity of the TBX1 protein, possibly through stabiliza-
tion of the protein-protein or protein-DNA interaction.
We also conclude that TBX1 gain-of-function mutations
can result in the same phenotypic spectrum as haplo-
insufﬁciency caused by loss-of-function mutations or
deletions.
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